Evogene (EVGN) Capital Expenditures (2013 - 2026)
Evogene (EVGN) posted Capital Expenditures of -$2000.0 for Q1 2026, up 66.67% sequentially from -$6000.0 in Q4 2025, and up 98.35% YoY from -$1008.3 in Q1 2025.
Evogene (EVGN) Capital Expenditures (2013 - 2026) Analysis & Trends
Evogene has reported Capital Expenditures for 14 years, with the latest figure at -$2000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 98.35% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128000.0 (up 132.0% YoY) and the FY2025 annual result came in at -$135000.0, down 121.57% from the prior year.
- Capital Expenditures grew to -$2000.0 in Q1 2026 per EVGN's latest filing, from -$6000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $442000.0 in Q1 2022 and troughed at -$322000.0 in Q4 2024.
- A 5-year average of -$8823.5 and a median of -$2000.0 in 2026 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 474.42% in 2024, then jumped 346.43% in 2025.
- Over 5 years, Capital Expenditures stood at $199000.0 in 2022, then tumbled by 56.78% to $86000.0 in 2023, then plunged by 474.42% to -$322000.0 in 2024, then soared by 98.14% to -$6000.0 in 2025, then soared by 66.67% to -$2000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$2000.0, -$6000.0, and $125000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | -6,000.00 |
| Dec 31, 2025 | -6,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Dec 31, 2024 | -322,000.00 |
| Dec 31, 2024 | -322,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Mar 31, 2024 | -141,000.00 |
| Mar 31, 2024 | -141,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Dec 31, 2023 | 86,000.00 |